

APLISENS stabilizes sales in Q2 and focuses on delivering strategic objectives in 2025

The APLISENS Group generated revenues of nearly PLN 36.5 million in the second quarter of 2025, representing a 1.4% increase year-on-year. For the first half of 2025, sales amounted to PLN 71.8 million, down 8.7% compared with the record-high result achieved in H1 2024. Operating profit reached PLN 10.2 million, a decline of 35.1% y/y, EBITDA amounted to PLN 15.15 million (-24.4% y/y), and net profit came in at PLN 8.5 million (-33.1% y/y).

Revenue declines in the half-year comparison were visible across all key markets: domestic market (-2.4% y/y), European Union markets (-4.1% y/y), CIS markets (-26.8% y/y), and other export markets (-7.6% y/y). These results reflect a challenging macroeconomic environment, particularly in Europe and Eastern markets, as well as the high comparative base from 2024 (mainly in other export markets and in Kazakhstan). Nevertheless, in Q2 2025 alone, APLISENS maintained a stable level of sales, demonstrating the Company's ability to effectively adapt to changing market conditions.

"The results for the first half of 2025 primarily reflect the difficult economic environment across our core markets. Following a record year in 2024, we are seeing a normalization of demand, particularly in Europe and the CIS. The stabilization of sales in the second quarter, however, shows that we can adapt to new conditions and sustain a strong market position," said **Adam Żurawski, President of the Management Board of APLISENS S.A.**

The Management Board remains committed to executing the strategic objectives set out in the 2023–2025 development plan, although their delivery will require intensified efforts in the coming months. To achieve the revenue targets over the full strategy horizon, the domestic market requires approximately PLN 23.5 million of additional sales, while the CIS markets require around PLN 5.3 million. According to the Management Board, these levels are achievable in H2, particularly in the domestic segment. In other markets, the dynamics assumed in the strategy will not be fully met, but the Company continues to pursue maximum revenue potential and maintain a stable position in a demanding environment.

In the second half of 2024, the Company launched initiatives to align employment levels with current sales volumes. This process will continue in the coming months, with its effects expected to be visible in H2 2025. Similar measures are also being implemented at subsidiary CZAH-POMIAR Sp. z o.o.

At the end of the first half of 2025, the Group remained in a solid liquidity position, holding over PLN 22.5 million in cash and short-term financial assets, without drawing on any credit lines. The strong financial standing enabled further distributions to shareholders. In July 2025, APLISENS repurchased 292,163 treasury shares with a total value of PLN 5.87 million, representing 2.62% of share capital, and in August it paid out PLN 7.8 million in dividends (PLN 0.70 per share), equal to 38.02% of 2024 net earnings.

At the same time, the Company continues to advance key development projects. In June, APLISENS signed a funding agreement for the development and implementation of a new generation of electromagnetic flowmeters, covering both R&D activities and investment in production infrastructure in Radom. The project, with a total cost of PLN 25.9 million and funding of PLN 9.4 million, is expected to strengthen APLISENS' technological advantages in the coming years.

"Investments in innovation and geographical diversification are of key importance to our future. The new generation flowmeter project is an example of initiatives that will not only strengthen our technological

edge but also enhance our competitiveness in international markets. We aim to continue developing on solid financial foundations, while ensuring shareholder value creation. Our objective is for the second half of the year to bring a clear improvement in results and enable us to move closer to our strategic targets,” **Żurawski** emphasized.

In H1 2025, the APLISENS Group incurred capital expenditures of approximately PLN 4 million. The largest portion of this amount (64%) was allocated to machinery and equipment purchases, 29% to research and certification, and the remaining 7% to investments in subsidiaries.